MA45552A - Compositions destinées au traitement de l'amylose - Google Patents

Compositions destinées au traitement de l'amylose

Info

Publication number
MA45552A
MA45552A MA045552A MA45552A MA45552A MA 45552 A MA45552 A MA 45552A MA 045552 A MA045552 A MA 045552A MA 45552 A MA45552 A MA 45552A MA 45552 A MA45552 A MA 45552A
Authority
MA
Morocco
Prior art keywords
amylosis
compositions
treatment
Prior art date
Application number
MA045552A
Other languages
English (en)
Inventor
Spencer D Guthrie
Gene G Kinney
Martin Koller
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MA45552A publication Critical patent/MA45552A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045552A 2016-06-30 2017-06-30 Compositions destinées au traitement de l'amylose MA45552A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30

Publications (1)

Publication Number Publication Date
MA45552A true MA45552A (fr) 2019-05-08

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045552A MA45552A (fr) 2016-06-30 2017-06-30 Compositions destinées au traitement de l'amylose

Country Status (14)

Country Link
US (2) US20190169280A1 (fr)
EP (1) EP3478713B1 (fr)
JP (2) JP2019519584A (fr)
DK (1) DK3478713T3 (fr)
ES (1) ES2914781T3 (fr)
HR (1) HRP20220979T8 (fr)
HU (1) HUE059400T2 (fr)
LT (1) LT3478713T (fr)
MA (1) MA45552A (fr)
PL (1) PL3478713T3 (fr)
PT (1) PT3478713T (fr)
RS (1) RS63446B1 (fr)
SI (1) SI3478713T1 (fr)
WO (1) WO2018005967A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020019172A2 (pt) * 2018-03-23 2021-01-26 Prothena Biosciences Limited tratamento e profilaxia de amiloidose
US20220213223A1 (en) * 2019-02-12 2022-07-07 Prothena Biosciences Limited Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
CA3132780A1 (fr) * 2019-03-05 2020-09-10 Prothena Biosciences Limited Procedes de traitement de l'amylose al
EP4022062A1 (fr) * 2019-08-30 2022-07-06 Alnylam Pharmaceuticals, Inc. Chaîne légère neurofilamentaire (nfl) en tant que biomarqueur pour la polyneuropathie liée une amylose à transthyrétine
KR20230039640A (ko) * 2020-06-22 2023-03-21 엔지엠 바이오파마슈티컬스, 아이엔씨. Lair-1-결합제 및 이의 사용 방법
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
CA2710984C (fr) 2007-12-28 2018-05-29 Elan Pharmaceuticals, Inc. Traitement et prophylaxie de l'amylose
CN104023743B (zh) * 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法

Also Published As

Publication number Publication date
WO2018005967A1 (fr) 2018-01-04
HUE059400T2 (hu) 2022-11-28
JP2019519584A (ja) 2019-07-11
US20210079078A1 (en) 2021-03-18
EP3478713A1 (fr) 2019-05-08
LT3478713T (lt) 2022-06-10
DK3478713T3 (da) 2022-06-20
EP3478713B1 (fr) 2022-05-11
ES2914781T3 (es) 2022-06-16
PL3478713T3 (pl) 2022-10-10
PT3478713T (pt) 2022-05-27
SI3478713T1 (sl) 2022-06-30
HRP20220979T8 (hr) 2023-02-03
US20190169280A1 (en) 2019-06-06
RS63446B1 (sr) 2022-08-31
HRP20220979T1 (hr) 2022-11-11
JP2022121658A (ja) 2022-08-19

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA47719A (fr) Esketamine pour le traitement de la dépression
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA44486A (fr) Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
MA46180A (fr) Analogues de l'amyline
MA41449A (fr) Polythérapies pour le traitement de cancers
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
FR3056393B1 (fr) Orthese d'extension de machoires
MA42999A (fr) Polythérapie pour le traitement de malignités
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo
DK3638293T5 (da) Sammensætninger til behandling af cancer
MA54276A (fr) Montélukast de traitement de l'ostéoarthrite érosive de la main